All News

An analysis of exchange premiums finds that older adults with incomes just above the premium subsidy cutoff (400% of poverty), particularly in rural areas where premiums are highest, have the most severe affordability challenges.

Compared with other drug regimens, a carfilzomib-based regimen resulted in longer time to next treatment, as well as longer overall survival and improved 24-month survival, among patients with relapsed or refractory multiple myeloma (RRMM).

FDA Commissioner Scott Gottlieb, MD, will resign his post in about a month. The physician has been active in fighting youth e-cigarette use, encouraging generic drug competition, and in modernizing approval processes while leading the FDA. Reports said he wants to spend more time with his family.

A second patient has been reported to have been cured of infection with HIV since the start of the epidemic; thousands have reported complications to the FDA with medical devices and implants; a 30-person national ethics committee has been appointed in China to oversee high-risk clinical trials.

Researchers discovered a strong correlation between cerebral small vessel diseases and motor symptoms in patients with Parkinson disease, according to a recent cross-sectional study.

The results come after the American Diabetes Association and the American College of Cardiology have recently issued guidelines calling for the use of GLP-1 receptor agonists for patients with type 2 diabetes and cardiovascular risk.

Another study dispelling concerns about links between the measles, mumps, rubella (MMR) vaccine to autism has been released, this time with additional focus about subgroups of children.

Two abstracts presented at the Transplantation and Cellular Therapy Meetings analyzed the detection of minimal residual disease during and after hematopoietic stem cell transplantation.

The change comes on the heels of hearings in Congress where insulin costs were held up for scrutiny.

Some patient advocacy groups opposing Medicare changes have received funding from pharma companies in the past; new techniques allow scientists to target individual cells for analysis; rural nursing homes continue to close.

Low-value care that offers no benefit to patients, or can actually cause more harm than good, is costly to patients and the healthcare system. While low-value services are being identified and measured, it has been more difficult to reduce the use of low-value care.

According to recently published research, vitamins B12 and B9 can lower levels of homocysteine, improve anemia status, and boost physical health in patients with relapsing remitting multiple sclerosis (MS).

A recent study measured exhaled breath condensate (EBC) content that contained ultrafine particles (UFP) as a reflection of inflammation and oxidative stress in patients with chronic obstructive pulmonary disease (COPD) and as a marker of exacerbations.

In a recent study, researchers looked to analyze the association of migraine that presents with visual aura with atrial fibrillation (AF) as migraines with a visual aura are associated with a cardioembolic stroke risk.

A technology update, a new drug approval, and a drug recall due to more impurities.

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion that an orphan drug, volanesorsen (Waylivra), receive a conditional marketing authorization. The drug would be the first medication approved for the treatment of the familial chylomicronemia syndrome (FCS).

Organizations and agencies marked Rare Disease Day this week. Here are 5 things to know about rare disease.

Short-term investments pertaining to the distribution of PrEP are expected to result in long-term cost-savings and promote significant health benefits following its introduction in Germany, according to a new modelling study.

Hematological consequences of severe chronic neutropenia vary based on the underlying etiology of the condition, according to a study abstract presented at the 60th American Society of Hematology Annual Meeting & Exposition.

Since carfilzomib was approved at a 27 mg/m2 twice-weekly dose, it has since been optimized at 56 mg/m2 twice-weekly and a recent study found benefits of a 70 mg/m2 once-weekly dose. However, most patients are still treated with the original approval dosage, suggesting they might be undertreated.

This week, the top managed care news included pharmaceutical executives appearing before a Senate drug pricing hearing; HHS finalizing a Title X rule change; and an analysis that found travel and wait times for healthcare services come with a high price.

Scientists at the National Institutes of Health have recently found that biologic age, or a DNA-based estimate of a person’s age, is associated with future development of breast cancer.

Nearly 10% of drug approvals in 2018 were generic products for branded drugs that had no FDA-approved generics.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Senator Bill Cassidy, R-Louisiana, is working with Democratic colleagues Michael Bennet of Colorado and Maggie Hassan of New Hampshire to introduce a bill this month to stop patients from getting surprise medical bills; the FDA warned a major Canadian drug distributor, CanaRx to stop selling unapproved and mislabeled medicines to Americans looking to save money on prescriptions; Democratic leaders in the House of Representatives are trying to keep the chamber united behind narrower proposals aimed at strengthening the Affordable Care Act and lowering drug prices in the wake of the introduction of a Medicare for All bill.

The vast majority of patients with COPD require greater motivation to seek help when symptom changes occur and are unaware of their increased risk of developing lung cancer, according to new research.

AstraZeneca and Merck will present full results at a future meeting; Myriad Genetics will file a supplemental application for its companion diagnostic.

How to improve patient-reported measurement in oncology valued-based care is the focus of a new report from The National Pharmaceutical Council and Discern Health.

Here are 5 interesting findings from the February 2019 issue of AJMC®.

Between 2014 and 2017, antivirals were consistently the number 1 most costly outpatient drug group for Medicaid, and HIV antiretrovirals and hepatitis C drugs accounted for more than 90% of spending on these antivirals.